Weiping Chen

Plasma Neuro fi lament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration

Sheng-Yang M. Goh, A. Toga, L. Petrucelli, 2022 .

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Nita A. Farahany, P. Andersen, M. Benatar, 2022, Neurotherapeutics.

PAN-TAU ANTIBODY BIIB076 EXHIBITS PROMISING SAFETY AND BIOMARKER PROFILE IN CYNOMOLGUS MONKEY TOXICITY STUDY

G. Cantone, C. Wager, C. Stebbins, 2017, Alzheimer's & Dementia.

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration

Sheng-Yang M. Goh, A. Toga, L. Petrucelli, 2021, Neurology.

Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration

P. Weinreb, I. Nestorov, T. Bohnert, 2018, Fluids and barriers of the CNS.

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Nita A. Farahany, P. Andersen, M. Benatar, 2022, Neurotherapeutics.

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration

A. Toga, L. Petrucelli, B. Dickerson, 2021, Neurology.